About Meds Wolverine

What this publication is

Meds Wolverine reads the peer-reviewed research literature on BPC-157 TB-500 — the two-peptide "Wolverine" blend — and keeps it as two separate records. There is no clinic here and nobody clinical on staff; no page gives medical advice; nothing is made, stocked, or shipped. What the site does is read the record and mark where it stops.

The "meds" in the name describes our subject, not our services. It marks an interest in what the blend is studied for and in how regulatory and compounding access actually works — the questions a medicinally-minded reader brings — and nothing more. There is no dispensary here, no prescriber, and no storefront.

How we read the record

We treat the blend the way a data console treats two records. BPC-157 and TB-500 are logged separately, each finding tagged to the constituent it belongs to and carrying a verification status: VERIFIED for a citation-confirmed single-compound result, PRECLINICAL for rodent-only or in-vitro work, EXTRAPOLATED for the theoretical synergy claim, and NO-HUMAN-DATA for the gaps the combination leaves open.

That discipline is the whole editorial stance. The blend's marketing implies a unity the chemistry does not support, so we keep the two records distinct, attribute every quantitative claim to a study, and flag the combination row as empty because no controlled trial has filled it. Where the human data belong to full-length Thymosin Beta-4 rather than the TB-500 fragment, we say so.

What we do not do

No dose, route, or protocol is recommended for any person. The site describes what was administered to which species at which dose by which route, and stops there. It sells neither the blend nor either constituent and links to no vendor. It offers no consultation, treatment, or prescription, and the editorial framing in the name is a stance toward the literature — not a claim about services. Every page is sourced; the full reference list is the spine of the site.